Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin

International Journal of Oncology

Volumn 43, Issue 2, 2013, Pages 365-374

  Uehara, Hisanori ^a   Takahashi, Tetsuyuki ^a   Izumi, Keisuke ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Bone metastasis; Osteoprotegerin; Placentaspecific 8; Prostate cancer; Retinol binding protein 4

Indexed keywords

CELL PROTEIN; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACENTA SPECIFIC 8; RETINOL BINDING PROTEIN 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DESTRUCTION; BONE LESION; BONE METASTASIS; CANCER INHIBITION; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; MICE; MICE, NUDE; OSTEOCLASTS; OSTEOLYSIS, ESSENTIAL; OSTEOPROTEGERIN; PROSTATIC NEOPLASMS; PROTEINS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RETINOL-BINDING PROTEINS, PLASMA; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84879625535     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1954     Document Type: Article

References (46)

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
2. Bubendorf L, Schopfer A, Wagner U, et al: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31: 578-583, 2000. (Pubitemid 30323983)
3. Brown JE, Cook RJ, Major P, et al: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumors. J Natl Cancer Inst 97: 59-69, 2005.
4. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664, 2004.
5. Demers LM: Bone markers in the management of patients with skeletal metastases. Cancer 97: 874-879, 2003.
6. Percival RC, Urwin GH, Harris S, et al: Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 13: 41-49, 1987. (Pubitemid 17040425)
7. Freedland SJ, Richhariya A, Wang H, Chung K and Shore ND: Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology 80: 293-298, 2012.
8. Coleman R, Gnant M, Morgan G and Clezardin P: Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104: 1059-1067, 2012.
9. Mundy GR: Mechanisms of osteolytic bone destruction. Bone 12 (Suppl 1): S1-S6, 1991.
10. Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998. (Pubitemid 28180851)
11. Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997. (Pubitemid 27199902)
12. Bucay N, Sarosi I, Dunstan CR, et al: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268, 1998. (Pubitemid 28213402)
13. Zhang J, Dai J, Qi Y, et al: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107: 1235-1244, 2001. (Pubitemid 32494540)
14. Corey E, Brown LG, Kiefer JA, et al: Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 65: 1710-1718, 2005. (Pubitemid 40478596)
15. Zhang J, Dai J, Yao Z, Lu Y, Dougall W and Keller ET: Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 63: 7883-7890, 2003. (Pubitemid 37466723)
16. Shipman CM and Croucher PI: Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63: 912-916, 2003. (Pubitemid 36278418)
17. Holen I, Croucher PI, Hamdy FC and Eaton CL: Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62: 1619-1623, 2002. (Pubitemid 34408480)
18. McGonigle JS, Giachelli CM and Scatena M: Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 12: 35-46, 2009.
19. Peddi P, Lopez-Olivo MA, Pratt GF and Suarez-Almazor ME: Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 39: 97-104, 2013.
20. Brown-Glaberman U and Stopeck AT: Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics 6: 89-99, 2012.
21. Uehara H, Kim SJ, Karashima T, et al: Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95: 458-470, 2003. (Pubitemid 36432420)
22. Uemura H, Yanagisawa M, Ikeda I, et al: Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial. Int J Clin Oncol: Apr 11, 2012 (Epub ahead of print).
23. Smith MR, Saad F, Coleman R, et al: Denosumab and bone-metastasis- free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379: 39-46, 2012.
24. Smith MR, Egerdie B, Hernandez Toriz N, et al: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361: 745-755, 2009.
25. Fizazi K, Lipton A, Mariette X, et al: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27: 1564-1571, 2009.
26. Lipton A, Steger GG, Figueroa J, et al: Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25: 4431-4437, 2007. (Pubitemid 350013849)
27. Lipton A, Fizazi K, Stopeck AT, et al: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48: 3082-3092, 2012.
28. Ford JA, Jones R, Elders A, et al: Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer 49: 416-430, 2013.
29. Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28: 5132-5139, 2010.
30. Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45, 2001. (Pubitemid 33741879)
31. Ting HJ, Hsu J, Bao BY and Lee YF: Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3. Cancer Lett 247: 122-129, 2007. (Pubitemid 44959414)
32. Bao BY, Hu YC, Ting HJ and Lee YF: Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene 23: 3350-3360, 2004.
33. Arah IN, Song K, Seth P, Cowan KH and Sinha BK: Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells. Anticancer Res 18: 1845-1849, 1998. (Pubitemid 28342602)
34. Fisher JL, Thomas-Mudge RJ, Elliott J, et al: Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 66: 3620-3628, 2006.
35. Flower DR: The lipocalin protein family: structure and function. Biochem J 318: 1-14, 1996.
36. Newcomer ME and Ong DE: Plasma retinol binding protein: structure and function of the prototypic lipocalin. Biochim Biophys Acta 1482: 57-64, 2000.
37. Tsutsumi C, Okuno M, Tannous L, et al: Retinoids and retinoid-binding protein expression in rat adipocytes. J Biol Chem 267: 1805-1810, 1992.
38. Kovacs P, Geyer M, Berndt J, et al: Effects of genetic variation in the human retinol binding protein-4 gene (RBP4) on insulin resistance and fat depot-specific mRNA expression. Diabetes 56: 3095-3100, 2007. (Pubitemid 350223647)
39. Graham TE, Yang Q, Bluher M, et al: Retinol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med 354: 2552-2563, 2006. (Pubitemid 43882351)
40. Yang Q, Graham TE, Mody N, et al: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436: 356-362, 2005. (Pubitemid 41065039)
41. Abel ED, Peroni O, Kim JK, et al: Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409: 729-733, 2001. (Pubitemid 32144519)
42. Abulaizi M, Tomonaga T, Satoh M, et al: The application of a three-step proteome analysis for identification of new biomarkers of pancreatic cancer. Int J Proteomics 2011: 628787, 2011.
43. Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR and Herndon JE II: Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 25: 5578-5583, 2007.
44. Mourtada-Maarabouni M, Watson D, Munir M, Farzaneh F and Williams GT: Apoptosis suppression by candidate oncogene PLAC8 is reversed in other cell types. Curr Cancer Drug Targets 13: 80-91, 2012.
45. Li Y, Rogulski K, Zhou Q, Sims PJ and Prochownik EV: The negative c-Myc target onzin affects proliferation and apoptosis via its obligate interaction with phospholipid scramblase 1. Mol Cell Biol 26: 3401-3413, 2006.
46. Rogulski K, Li Y, Rothermund K, et al: Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway. Oncogene 24: 7524-7541, 2005. (Pubitemid 41638028)